Echo IQ Reports AU$5.35 Million in Cash in December 2024 Quarter; Shares Fall 4%

MT Newswires Live

Jan 30, 2025

Echo IQ (ASX:EIQ) said it held AU$5.4 million in cash and cash equivalents at the end of the December 2024 quarter, according to a Thursday Australian bourse filing.

The firm expects to receive AU$1.2 million as part of a research and development tax rebate in the March quarter.

During the March quarter, it expects to convert its pipeline of large US hospital groups, device manufacturers, and pharmaceutical companies to increase integration and uptake of its heart disorder testing tool, EchoSolv AS.

The company also plans to finalize agreements with a US-based trial partner for a proposed validation study for its heart failure screening tool EchoSolv HF, the filing said. It will start the study after design approval from the US Food and Drug Administration ahead of formal submission for clearance.

Echo IQ's shares fell almost 4% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507969769"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507969769\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507969769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-30 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507969769","market":"sg","top_or_hot":-1,"title":"Echo IQ Reports AU$5.35 Million in Cash in December 2024 Quarter; Shares Fall 4%","media":"MT Newswires Live","content":"<html><body><p> Echo IQ (ASX:EIQ) said it held AU$5.4 million in cash and cash equivalents at the end of the December 2024 quarter, according to a Thursday Australian bourse filing.</p><p>The firm expects to receive AU$1.2 million as part of a research and development tax rebate in the March quarter.</p><p>During the March quarter, it expects to convert its pipeline of large US hospital groups, device manufacturers, and pharmaceutical companies to increase integration and uptake of its heart disorder testing tool, EchoSolv AS.</p><p>The company also plans to finalize agreements with a US-based trial partner for a proposed validation study for its heart failure screening tool EchoSolv HF, the filing said. It will start the study after design approval from the US Food and Drug Administration ahead of formal submission for clearance.</p><p>Echo IQ's shares fell almost 4% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Echo IQ Reports AU$5.35 Million in Cash in December 2024 Quarter; Shares Fall 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEcho IQ Reports AU$5.35 Million in Cash in December 2024 Quarter; Shares Fall 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-30 12:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Echo IQ (ASX:EIQ) said it held AU$5.4 million in cash and cash equivalents at the end of the December 2024 quarter, according to a Thursday Australian bourse filing.</p><p>The firm expects to receive AU$1.2 million as part of a research and development tax rebate in the March quarter.</p><p>During the March quarter, it expects to convert its pipeline of large US hospital groups, device manufacturers, and pharmaceutical companies to increase integration and uptake of its heart disorder testing tool, EchoSolv AS.</p><p>The company also plans to finalize agreements with a US-based trial partner for a proposed validation study for its heart failure screening tool EchoSolv HF, the filing said. It will start the study after design approval from the US Food and Drug Administration ahead of formal submission for clearance.</p><p>Echo IQ's shares fell almost 4% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507969769","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507969769","pubTimestamp":1738210914,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Echo IQ  said it held AU$5.4 million in cash and cash equivalents at the end of the December 2024 quarter, according to a Thursday Australian bourse filing.The firm expects to receive AU$1.2 million as part of a research and development tax rebate in the March quarter.During the March quarter, it expects to convert its pipeline of large US hospital groups, device manufacturers, and pharmaceutical companies to increase integration and uptake of its heart disorder testing tool, EchoSolv AS.The company also plans to finalize agreements with a US-based trial partner for a proposed validation study for its heart failure screening tool EchoSolv HF, the filing said. It will start the study after design approval from the US Food and Drug Administration ahead of formal submission for clearance.Echo IQ's shares fell almost 4% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4552":"Archegos爆仓风波概念","EIQ.AU":"ECHOIQ LTD","BK7016":"应用软件","BK4531":"中概回港概念","BK4108":"电影和娱乐","BK4526":"热门中概股"},"translate_title":"Echo IQ报告2024年12月季度现金为535万澳元；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EIQ.AU":0.9},"content_text":"Echo IQ (ASX:EIQ) said it held AU$5.4 million in cash and cash equivalents at the end of the December 2024 quarter, according to a Thursday Australian bourse filing.The firm expects to receive AU$1.2 million as part of a research and development tax rebate in the March quarter.During the March quarter, it expects to convert its pipeline of large US hospital groups, device manufacturers, and pharmaceutical companies to increase integration and uptake of its heart disorder testing tool, EchoSolv AS.The company also plans to finalize agreements with a US-based trial partner for a proposed validation study for its heart failure screening tool EchoSolv HF, the filing said. It will start the study after design approval from the US Food and Drug Administration ahead of formal submission for clearance.Echo IQ's shares fell almost 4% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}